

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

185,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Phytochemical Profile and Antiobesity Potential of *Momordica charantia* Linn.

Pushpa Anantrao Karale, Shashikant Dhawale
and Mahesh Karale

Abstract

Momordica charantia L. is growing in many tropical and subtropical regions; the fruits of bitter melon are also gradually becoming popular for treating diabetes and associated diseases. Over 248 compounds belonging to the lipids, phenolics and terpenoids class are reported by diverse studies. However, *M. charantia* L. appears to be an inimitable species that synthesizes a diverse range of natural products in the fruits, leaves, stems and roots. The cucurbitane types of triterpenes exist in the various tissues of the plant in their aglycone as well as glycosylated forms. The bitter melon seems to exert their lipid lowering and antiobesity effects via several mechanisms like PPARs, LXRs, SREBPs, and Sirts mediated fat metabolism in various tissues, prevent adipocyte hypertrophy and visceral fat accumulation. *M. charantia* L. has been comprehensively studied worldwide for its therapeutic properties to treat a number of diseases like diabetes, dyslipidaemia, obesity, and certain cancers. This chapter apparently displays an encompassing literature review on vast potential of bitter melon as antiobesity agent and assembles data on complex phytochemistry.

Keywords: obesity, phytochemicals, bitter melon, cucurbitane type terpenoids

1. Introduction

Momordica charantia L. or Bitter Melon, also known as balsam pear or Karela, is a vegetable and common food in Indian cuisine and has been used comprehensively in folk medicine. *Momordica charantia* L. is tropical or subtropical creeping belonging to family *Cucurbitaceae* and widely used as medicinal herb from ancient time (**Figure 1**). The Latin name *Momordica* means “to bite” referring to the serrated edges of the leaf, which appear as if they have been bitten. The major regions of *M. charantia* L. cultivation are Asia including China, India, Sri Lanka and Thailand, central and South America and North America [1]. In Ayurveda, the fruit is considered as tonic, stomachic, stimulant, emetic, antibilious, laxative and alterative. Bitter melon has been used in various Asian traditional medicine systems for a long time. It is well recognized, the plant is extensively in use in the Chinese, Indian Ayurvedic, and Indonesian systems of medicines as well as in Japan [2].

The therapeutic significance of the plant is symbolized by the fruits which contain about half a dozen seeds per gram of the fresh fruit. As the name implies, the fruits are bitter and bitterness enhance with the level of maturity and hence



Figure 1.

The image describes plant parts of *M. charantia* L. unripe fruit; ripe fruit and seeds of plant.

earlier harvesting required to battle bitter taste. The leaves and young shoots of bitter melon recognized to be used in traditional medicine as an herbal tea. The range of pharmacological activities reported for bitter melon is rapidly increasing in recent years and its claimed uses and potential applications for cancer and other diseases have been extensively reviewed. Likewise, the range of medicinal claims range from diabetes, hypertension, obesity, cancer, as well as AIDS. *M. charantia* L. possesses various beneficial effects, including anti-cancer, anti-viral, antioxidant, antiulcer, anti-obesity, anti-HIV, cytotoxic, anti-inflammatory, reduction of cholesterol, inhibition of protein tyrosine phosphatase 1B, and anti-osteoporosis [3]. This chapter aims to highlight the complex phytochemistry and extensive review on antiobesity potential of bitter melon with possible targets.

2. Plant profile

2.1 Botanical description

Cucurbitaceae family is known to comprise some 101 accepted genera and the genus *Momordica* L. itself comprises of some 50 accepted species within the family [4]. *M. charantia* L. was known previously by several synonyms including the *Cucumis argyi* H. Lev., *Cucumis intermedius* M. Roem., *Momordica anthelmintica* Schumach. & Thonn., *Momordica charantia* subsp. *abbreviata* (Ser.) Greb., *Momordica charantia* var. *abbreviata* Ser., *Momordica charantia* f. *muricata* (Willd.), *Momordica charantia* var. *muricata* (Willd.) Chakrav., *Momordica charantia* var. *pseudobalsamina* Griseb., *Momordica charantia* var. *zeylanica* Hitchc., *Momordica elegans* Salisb., *Momordica indica* L., *Momordica jagorana* K.Koch., *Momordica muricata* Willd., *Momordica papillosa* Peckolt ex Rosenthal., *Momordica roxburghiana* G. Don., *Momordica senegalensis* Lam., *Momordica thollonii* Cogn., *Momordica zeylanica* Mill. The botanical description of different parts of the plant demonstrated in **Table 1**. The taxonomic hierarchy of bitter melon within the plant kingdom is as follow:

Kingdom: Plantae
Subkingdom: Viridiplantae
Superdivision: Embryophyta
Division: Tracheophyta
Subdivision: Spermatophytina
Class: Magnoliopsida
Super order: Rosanae
Order: Cucurbitales

Plant parts	Description
Leaves	Broadly ovate to orbicular in outline, cordate, narrowly decurrent on to petiole, sparsely pubescent to densely villous on veins beneath, deeply palmately 3–7-lobed, lobes variously sinuate-dentate or lobulate. Leaf lamina 10 × 12.5 cm.
Flowers	Flowers are monoecious and solitary. Male flowers: peduncle 0.3–5 cm long; bract 2–17 mm long, broadly ovate or reniform, sessile, cordate, amplexicaul, pedicel 2–9.5 cm long. Receptacle-tube 1–5 mm long; lobes 3–7 mm long, ovate-lanceolate. Petals 1.0–2.5 cm long, pale to deep yellow, ovate to obovate. Female flowers: peduncle 0.2–5 cm long; bract 1–12 mm long; pedicel 1–10 cm long; ovary 8–11 × 2–4 mm, ovoid-rostrate to fusi-form, ridged, pilose on ridges, tuberculate; receptacle-tube 1–3 mm long, lobes 2–5 mm long, lanceolate; petals 0.7–1.2 cm long.
Fruits	Fruit 2.5–4.8 × 1.5–2.3 cm, ovoid-rostrate or ellipsoid, longitudinally ribbed and tuberculate, bright orange-red, dehiscent into 3 valves; fruit-stalk 3.4–15 cm long.
Seeds	Seeds 8–11, 4.5–8 × 2–3.5 mm, enveloped in sticky red pulp, ovate-elliptic to oblong in outline; faces flattened, sculptured, with sinuate edges; margins grooved.
Petiole	Petiole 0.5–7 cm long.

Table 1.
Botanical description of Momordica charantia Linn.

Family: Cucurbitaceae
Genus: *Momordica* Linn.
Species: *Momordica charantia* L.-balsampear

2.2 Phytochemistry

The main constituents of bitter melon are triterpenoids, saponins, protein, polysaccharides, steroid, alkaloid, lipid, and phenolic compounds. Several bioactive compounds of *M. charantia* L. have been recorded and the literature shown that these were responsible for various pharmacological effects as depicted in **Table 2** [5].

2.2.1 Triterpenoids

The most abundant phytochemical components of bitter melon fruits are the triterpenoids class of secondary metabolites, and are well-known for their bitterness

Sr. No.	Bioactive compounds	Distribution	Pharmacological effects
1	Triterpenoids	Leaves, stem, fruits	Chemo protective, anticancer, antioxidant, antidiabetic
2	Peptides and proteins	Seed	Antiviral, anti-tumor, immune suppressant, antimicrobial
3	Phenolics	Fruit and seed	Antioxidant, anti-inflammatory, immunostimulant
4	Saponin	Fruit, root, seed	Antihyperglycemic, hypolipidemic, antiviral, bacteriostatic
5	Polysaccharide	All parts of plant	Antioxidant, antidiabetic, immune enhancement, neuroprotective, antitumor
6	Lipid	Seed	Anti-tumor, antioxidant
7	Steroids	Fruit and pericarp	Antimicrobial

Table 2.
Bioactive components of Momordica charantia Linn. And their pharmacological effects.

and toxicity. These were divided in two types primarily the cucurbitane-type and to a less extent oleanane type which may occur either in their glycosylated or aglycone forms. The sugar monomers as β -D-glucopyranosyl, β -D-allopyranosyl, β -D-xylopyranosyl occur in cucurbitane-type triterpenes either by their own as O-linked glycosides, or in different combinations as disaccharides or polysaccharides. The rare glycoside in these compounds was the 3-keto-glucoside [6]. An extremely large and certainly exhibited 193 number of cucurbitane-type triterpenes isolated from bitter melon having various pharmacological effects (**Table 3**) [7]. The fruits are predominance source of terpenoids with great deal of structural diversity but the leaves, stems and roots have also been shown to be good sources of these compounds [8].

Momordicosides A and B were isolated firstly from the seeds of bitter melon fruits; While, Momordicosides C, D and E were isolated as minor components of the seeds [9]. The study on the fruits of *M. charantia* L. further added a Momordicosides F1, F2, G, I, K and L as novel compounds in previous one [10]. The Momordicosides I and Momordicosides M along with other compounds have also been isolated from the fruits of bitter melon [11]. Further additions of Momordicosides M-O as a new compound were confirmed by chemical examination of the fresh fruits [12]. The Vietnamese origin dried fruits of *M. charantia* had shown existence of an auxiliary three pioneering Momordicosides U, V and W. The cucurbitane-type triterpenes which are known to be responsible for the bitterness of the leaves and vines of the *M. charantia* L. are Momordicines. The Momordicine IV and the malonyl derivative of Momordicine II, Momordicine V was readily available in the leaves of bitter melon. The isolation of Momordicines VI, VII, and VIII were first confirmed from the stems and leaves of bitter melon [13].









The Goyaglycosides-a, -b, -c, -d, -e, -f, -g, and -h were isolated from the fresh fruits of Japanese *M. charantia* L. A novel compound Goyaglycoside I was an additional triterpene isolated from the immature fruit of bitter melon [14]. The novel Cucurbitane-type triterpene called karavilagenins A-C and five new triterpene glycosides called karavilosides I-V were isolated from the dried fruit of *M. charantia* L. [15]. The three novel compounds that they names charantosides A, B and C were obtained from fruits of bitter melon. The methanol extracts of the fruits of Japanese *M. charantia* L. shown charantosides I, II, III-VI, VII and VIII, however charantoside IX and X were other novel compounds reported by the studies [16].










Another group of interesting triterpenoids are those known by their trivial names kuguacins. Kuguacins A-E and Kuguacins F-S were isolated from the roots and the leaves of bitter melon plant respectively [17]. Kuguacins II-VI was novel compounds isolated together with various other known compounds from the fruit of *M. charantia* L. From the aqueous ethanolic extracts of fresh fruits isolated eight novel cucurbitane-type glycosides that they named kuguasaponins A-H. The ethanolic extract of fruits of *M. charantia* L. identified 15 cucurbitane-type triterpene glycosides including 4 new compounds, kuguasides A-D [18].









2.2.2 Flavonoids and phenolic compounds

A number of phenolic compounds with many biological activities have been isolated from bitter melon including, coumaric, caffeic, and ferulic acids as well as the caffeic acid ester, chlorogenic acid, Benzoic, gallic and gentisic acid. The major flavonoids and phenolic acids in the dried leaves of bitter melon were also analyzed and found to be rutin, gentisic acid and coumaric acid [19]. While the phenolic acids and flavonoids as well as their glycosides can be readily extracted by water, their non-polar derivatives may be present in the oil components of the plant.

Phytochemical Name	Plant parts	Chemical structure	Pharmacological effects
Momordicoside A & B	Fruits and seeds		Antidiabetic, anti-obesity, Anticancer
Momordicoside K	Leaves, fruits and roots		Antiproliferative, Hypoglycemic, Anti-obesity, Antioxidant
Momordicoside I & F1	Fruits		Antiproliferative, Hypoglycemic, anti-obesity, Disaccharidase
Momordicoside G & F2	Leaves and fruits		Antiproliferative, Hypoglycemic, Anti-obesity
Momordicine I & II	Leaves, vines and fruits		Cytotoxic, Anti-inflammatory, Antiviral, Immunomodulatory, Anti-obesity
Goyaglycoside-a & b	Leaves and vines		Antiproliferative, Hypoglycemic, Anti-obesity, Anticancer
Goyaglycoside-c & d	Fruits		Antiproliferative, Hypoglycemic, Anti-obesity, Anticancer
Goyaglycoside-e	Fruits		Cytotoxic, Anti-obesity, Antidiabetic

Phytochemical Name	Plant parts	Chemical structure	Pharmacological effects
Goyaglycoside-f	Fruits		Anti-obesity, Antidiabetic
Goyaglycoside-g	Fruits		Hypoglycemic, Anti-obesity
Goyaglycoside-h	Fruits		Hypoglycemic, Anti-obesity
Kuguacin B	Roots		Anticancer, Antidiabetic
Kuguacin C & D	Roots		Anti-HIV-1, Antidiabetic
Kuguacin E	Roots		Anti-HIV-1, Hypoglycemic
Kuguacin F	Leaves and vines		Hypoglycemic, Lipid lowering
Kuguacin G	Leaves and vines		Antidiabetic, Anti-obesity, Anticancer

Phytochemical Name	Plant parts	Chemical structure	Pharmacological effects
Kuguacin K	Leaves and vines		Anticancer, Antiproliferative, Hypoglycemic
Kuguacin H	Leaves and vines		Hypoglycemic, Antiproliferative
Kuguacin I	Leaves and vines		Anticancer, lipid lowering
Kuguacin J	Leaves and vines		Anticancer, Hypoglycemic
Kuguacin L	Leaves and vines		Antiproliferative, Hypoglycemic
Kuguacin M	Leaves and vines		Hypoglycemic, Anticancer
Kuguacin P & Q	Leaves and vines		Hypoglycemic, Antiproliferative
Kuguacin R	Leaves, stems and fruits		Antioxidant, Hypoglycemic, lipid lowering
Kuguacin S	Leaves and vines		Lipid lowering, hypoglycemic

Phytochemical Name	Plant parts	Chemical structure	Pharmacological effects
Charantoside I	Fruits		Hypoglycemic, Anti-obesity
Charantoside II	Fruits		Hypoglycemic, Anti-obesity
Charantoside III	Fruits		Hypoglycemic, Anti-obesity
Charantoside IV	Fruits		Hypoglycemic, Anti-obesity
Charantoside V	Fruits		Hypoglycemic, Anti-obesity
Charantoside VII	Fruits		Hypoglycemic, Anti-obesity
Charantoside VIII	Fruits		Hypoglycemic, Anti-obesity
Goyasaponin I	Fruits		Hypoglycemic, Anti-obesity







Phytochemical Name	Plant parts	Chemical structure	Pharmacological effects
Goyasaponin II	Fruits		Hypoglycemic, Anti-obesity
Goyasaponin III	Fruits		Hypoglycemic, Anti-obesity
Karavilagenin C	Fruits		Antidiabetic
Karaviloside I, II & III	Fruits		Antiproliferative, Antidiabetic, Hypolipidemic
Kuguaglycoside G	Roots		Cytotoxic, Antiproliferative, Hypoglycemic, Anticancer
Momordicinin	Fruits		Antidiabetic, Anti-obesity, lipid lowering

Table 3.
*Pharmacological effects of cucurbitane type of triterpenoids of *Momordica charantia*.*

2.2.3 Other components

Other than the bioactive compounds, unsaturated fatty acids, alkaloids, amino acids minerals and vitamins are also present in bitter melon. The extracts of bitter melon shows nine kinds of unsaturated fatty. It has also been demonstrated that 12, 13 and 12 carbon fatty acids are found in young, mature, and senescent leaves of *M. charantia* L. representing 87.3%, 95.25%, and 83.11% of the total fatty acids respectively. The contents of total amino acids and the free amino acids of *M. charantia* L. were 11.99% and 2.36% as determined by acid hydrolysis and amino acid analysis. In addition, bitter melon is a natural source of vitamins; ascorbic acid was detected in the range of 440–780 mg in the fruit fraction. Vicine is an alkaloidal agent that has been isolated from the seeds of bitter melon, which is responsible for hypoglycaemic activity [20].

3. Antiobesity and lipid lowering effects

The various experimental studies reported decrease in serum TC, TG and LDL-C concentrations and an increase in serum high density lipoprotein-cholesterol (HDL-C) for bitter melon by different authors. The action of bitter melon in lowering fat has been supported by plentiful studies, its effect on the level of serum FFAs have been contradictory with some authors showing reduction, some shown same level, and others reported an increased levels. For example, the serum FFAs concentration increased in obese rats treated with bitter melon shown by Chen et al. [21]. An increased level of TG and LDL-C in the serum that may arises due to either overproduction by the liver or defective removal from the circulation or the overall dyslipidaemia in diabetes. It is not clear why bitter melon increase the serum level of FFAs. It may facilitate fat mobilization due to the suppression of lipogenesis or lipid deposition. While other revealed *M. charantia* L. could lower the serum and liver TG levels [22].

The findings of experimental research conclude that, *M. charantia* L. may reduce the fasting insulin, TG, cholesterol and epididymal fat, which were increased by HFD. The dwindling of insulin resistance, improves glucose tolerance, and increases insulin signaling under HFD-induced insulin-resistance and elevated serum lipids may also shown by bitter melon. The administration of an aqueous extract of unripe fruits of bitter melon improved glucose and insulin tolerance together with inhibition of plasma apoB-100 and apoB-48. The animal study had shown that, the evidence of a potent inhibitor of apoB secretion and TG synthesis as well as the plasma lipid and VLDL effects of bitter melon juice [23]. Overall the studies on the fruits, seeds, and aerial parts of *M. charantia* Linn have been shown to reduce adiposity, lower serum insulin and normalize glucose tolerance in rats fed with a HFD. The body weight and visceral fat mass of bitter melon treated obese rats were shown to be lowered [24].

While further study revealed that, bitter melon supplementation into HFD notably suppressed the levels of fatty acid synthase (FAS), acetyl-CoA carboxylase-1 (ACC-1), lipoprotein lipase (LPL) and adipocyte fatty acid binding protein [25]. Water extract of *M. charantia* L. fruits at a dose 1 g/Kg body weight revealed to be effectual in improving the obesity-induced hyperglycaemia and hyperleptinemia [26]. This in progression propose that bitter melon can reduce insulin resistance, visceral fat accumulation and adipocyte hypertrophy probably by down-regulating the expression of key lipogenic genes or proteins in adipose tissues. Aqueous fruit extract of *M. charantia* L. significantly reduce the level of serum TG, TC, LDL and VLDL at a dose of 350 mg/Kg body weight in experimental rats [27]. Numerous

animal studies have been designated the efficacy of bitter melon in the amelioration of weight gain and regulation of lipid metabolism [28].

The methanolic extract of fruit of bitter melon showed antidiabetic and antihyperlipidemic action during different seasons of the year, this suggests that antidiabetic and hypolipidemic activity of *M. charantia* L. may fluctuate on quantity and quality of active constituents during different seasons of the year and reach the peak during spring [29]. The bitter melon seed oil had shown significantly decreased in body-weight, Lee's index, fat index and adipose size in the HFD mice. Meanwhile, the serum FFAs levels returned to normal at the dosage of 10 g/kg [30]. *Momordica charantia* L. extracts have anti-obesity effects and the ability to modulate lipid profile of mice fed a HFD by suppressing body weight gain, visceral tissue weight, plasma and hepatic lipid concentrations, and lipid peroxidation along with increasing lipid metabolism. The plasma TG, TC, and LDL-C levels along with hepatic TG and TC concentrations considerably lowered in mice fed a HFD by *Momordica charantia* L. extracts. Also elevated plasma HDL-C levels and fecal TG concentration shown in animals treated with the extracts. The extracts comprise anti-obesity effects in mice fed a HFD by inhibiting lipid peroxidation whereas increasing lipid metabolism [31]. Bitter melon extract showed useful benefit on body weight gain and fat deposition.

Moreover, bitter melon reduced the lipid accumulation during differentiation from a pre-adipocyte to adipocyte and down-regulated PPAR [32]. PPAR is considered the master regulator of adipogenesis during differentiation of pre-adipocyte to adipocyte [33]. Bitter melon juice inhibited adipocyte differentiation by reducing PPAR, SREBP, and perilipin mRNA gene expression and by increasing lipolysis in primary human adipocyte [34]. Several transcriptional regulatory factors like AMPK, PPAR, and PGC-1 regulate the mitochondrial biogenesis, which would be a possible way of increasing lipid metabolism and utilization in energy demanding cells and tissues [35]. PGC-1 stimulates mitochondrial biogenesis and respiration in multiple cell types and modulates biological programs normally associated with increased oxidative metabolism. Also decreased plasma level of TGs, cholesterol, and FFA in plasma of rats fed a HF diet revealed by bitter melon supplementation due to up regulation and activation of PGC-1 [36].

Bitter melon affects on various body organs to treat obesity and diabetes as [37]:

1. Liver

- Increased β -oxidation
- Increased PPAR- α and PPAR-gamma expression
- Increased expression of the transcription coactivator PGC-1 α
- Decreased fatty acid synthesis
- Decreased fat

2. Pancreas

- Increased insulin secretion
- Prevents cell damage
- Increased PPAR- α and PPAR- gamma expression in skeletal muscle

3. Fat cells

- Inhibited adipocyte hypertrophy
- Inhibited adipocyte differentiation
- Increased PPAR-gamma expression
- Increased expression of the transcription co-activator PGC-1 α
- Decreased visceral fat mass

AMPK synchronized PPAR and PGC-1 activation encouraged most of the transcriptional signal to augment fatty acid oxidation and mitochondrial function [38]. Recent investigation also reported that increased hepatic AMPK p, AMPK, AMPK-2, and Sirt1 content in HF diet fed mice with supplementation of 1.2% bitter melon extract [39]. LXRs were first recognized as orphan members of the nuclear receptor plays an important role in lipid and cholesterol metabolism and oxidized derivatives of cholesterol act as ligands for the LXRs. A high cholesterol diet fed mice develop enlarged fatty livers, degeneration of liver cells, high cholesterol levels in liver, and impaired liver function by LXR knockout [40]. The *M. charantia* L. extract supplementation decreased hepatic LXR which was responsible for decreased serum TC and LDL-C, HDL-C in high cholesterol diet Wistar rats [41]. Bitter melon extract was a potent inhibitor of lipogenesis and stimulator of lipolysis in 3 T3-L1 pre-adipocyte shown by researcher [42].

4. Toxic effects

The severe adverse reactions were not reported during the short term studies while extensive data on the potential toxic effect of bitter melon are not available. Bitter melon fruits are edible and assumed to be well tolerated, at the same time toxicological evidences were reported to discover its therapeutic potential for diabetes. The two cases of acute intoxication reported after taking bitter melon tea [43]. The fruit and seeds demonstrated greater toxicity than the leaf or aerial parts of the plant. Abdominal pain as a side effect has also been reported in some studies [44]. The antifertility and abortifacient effects of the *M. charantia* L. reported in animals also value advance investigation. An acute disease favism characterized by hemolytic anemia, in individuals with a hereditary loss of the enzyme glucose-6-phosphatase has been shown by vicine found in fava bean. Consequently, the presence of vicine in bitter melon seeds was also suggested to put patients with glucose-6-phosphatase deficiency at risk [45]. Although there have been no reports on favism induced by bitter melon, individuals susceptible to the disease should avoid eating the fruit.

Several studies have been directed to reduce the bitterness of *M. charantia* L. preparations attributes to the triterpene compounds and increasing tolerability by the general public through various formulation approaches. Some recent studies used β -cyclodextrin at 0.25–2% concentrations to improve sensory quality, total phenolic content, antioxidant activity and antidiabetic potential of *M. charantia* L. juice [46]. Various encapsulation methods of bitter melon extracts along with optimized spray-drying techniques were also scrutinized to obtain the powder [47].

5. Conclusion

M. charantia L. has been broadly studied globally for its medicinal properties and to treat a number of diseases like diabetes, dyslipidaemia, obesity, and certain cancers. The extracts of fruits and different compounds seem to exert their beneficial effects via several mechanisms like PPARs, LXRs and SREBPs mediated fat metabolism in various tissues, reduces visceral fat accumulation and adipose hypertrophy. Isolated compounds from this plant like cucurbitane type of terpenoids, flavonoids and phenolic acids possesses antiobesity potential. These mechanisms will be directly related to controlling and treating diabetes mellitus, dyslipidaemia, obesity and related cardiovascular complications. Thus, further studies are required to conduct more double blind randomized trials with bitter melon extracts in obese population. In this chapter, we summarized phytoconstituents of bitter melon and its antiobesity potential. This compilation of phytochemicals and antiobesity activity of *Momordica charantia* L. will help the researchers in designing new untried strategies.

Author details


Pushpa Anantrao Karale^{1*}, Shashikant Dhawale¹ and Mahesh Karale²

1 Department of Pharmacology, School of Pharmacy, Swami Ramanand Teerth Marathwada University, Nanded, Maharashtra, India

2 Department of Microbiology, Dayanand Science College, Latur, Maharashtra, India

*Address all correspondence to: pushpakarale7711@gmail.com

IntechOpen

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

References

- [1] Subratty AH, Gurib-Fakim A, Mahomoodally F. Bitter melon: An exotic vegetable with medicinal values. *Nutr Food Sci* 2005;35:143–147.
- [2] Grover JK, Yadav SP. Pharmacological actions and potential uses of *Momordica charantia*: A review. *J Ethnopharmacol* 2004;93:123–132.
- [3] Fang EF, Ng TB. Bitter gourd (*Momordica charantia*) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and anti-tumor properties. *Curr Mol Med* 2011;11(5):417–436.
- [4] Joseph B, Jini D. Antidiabetic effects of *Momordica charantia* (bitter melon) and its medicinal potency. *Asian Pac J Trop Dis* 2013;3(2):93–102.
- [5] Svobodova BB, Calhelha L, Heleno RC, Alves S, Walcott MJ. Bioactive properties and phenolic profile of *Momordica charantia* L. medicinal plant growing wild in Trinidad and Tobago. *Ind Crop Prod* 2017;95:365–373.
- [6] Akihisa T, Higo N, Tokuda H, Ukiya M, Akazawa H, Tochigi Y. Cucurbitane-type triterpenoids from the fruits of *Momordica charantia* and their cancer chemo-preventive effects. *J Nat Prod* 2007;70:1233–1239.
- [7] Karale P., Dhawale S. C., Karale M. A. Antiobesity potential and complex phytochemistry of *Momordica charantia* Linn. With promising molecular targets. *Indian J Pharm Sci.* 2020; 82(4): 548–561.
- [8] Chang CI, Chen CR, Liao YW, Cheng YW, Chen YC, Chou CH. Cucurbitane-type triterpenoids from *Momordica charantia*. *J Nat Prod* 2006; 69(8):1168–1171.
- [9] Miyahara Y, Okasbe H, Yamauchi T. Studies on the constituents of *Momordica charantia* L. II. Isolation and characterization of minor seed glycosides, momordicosides C, D and E. *Chem Pharm Bull* 1981;29:1561–1566.
- [10] Okabe H, Miyahara Y, Yamauchi T. Structures of momordicosides F1, F2, G, I, K and L, novel cucurbitacins in the fruits of *Momordica charantia* L. *Tetrahedron Lett* 1982a; 23(1):77–80.
- [11] Li QY, Liang H, Chen HB, Wang B, Zhao YY. A new cucurbitane triterpenoid from *Momordica charantia*. *Chin Chem Lett* 2007; 18(7):843–845.
- [12] Nguyen XN, Phan VK, Chau VM, Ninh KB, Nguyen XC, Le MH. Cucurbitane-type triterpene glycosides from the fruits of *Momordica charantia*. *Magn Reson Chem* 2010; 48:392–396.
- [13] Okabe H, Miyahara Y, Yamauchi T. Structures of momordicine I, II and III. The bitter principles in the leaves and vines of *Momordica charantia* L. *Chem. Pharm. Bull* 1982b;30:4334–4340.
- [14] Murakami T, Emoto A, Matsuda H, Yoshikawa M. Medicinal foodstuffs XXI. Structures of new cucurbitane-type triterpene glycosides, goyaglycosides-a, -b, -c, -d, -e, -f, -g, and -h, and new oleanane-type triterpene saponins, goyasaponins I, II, and III, from the fresh fruit of Japanese *Momordica charantia* L. *Chem. Pharm. Bull* 2001;49:54–63.
- [15] Nakamura S, Murakami T, Nakamura J, Kobayashi H, Matsuda H, Yoshikawa M. Structures of new cucurbitane-type triterpenes and glycosides, karavilagenins and karavilosides, from the dried fruit of *Momordica charantia* L. in Sri Lanka. *Chem Pharm Bull* 2006;54:1545–1550.
- [16] Zhao GT, Liu JQ, Deng YY, Li HZ, Qiu MH. Cucurbitane-type triterpenoids from the stems and leaves of *Momordica charantia*. *Fitoterapia* 2014;95:75–82.

- [17] Yue J, Sun Y, Xu J, Cao J, Zhao Y. Cucurbitane triterpenoids from the fruit of *Momordica charantia* L. and their anti-hepatic fibrosis and anti-hepatoma activities. *Phytochemistry* 2019;157: 21–27.
- [18] Yue J, Xu J, Cao J, Zhang X, Zhao Y. Cucurbitane triterpenoids from *Momordica charantia* L. and their inhibitory activity against α -glucosidase, α -amylase and protein tyrosine phosphatase 1B (PTP1B). *J Funct Foods* 2017;37:624–631.
- [19] Minh NP. Extraction of polyphenol in bitter melon (*Momordica charantia*). *IJMRD* 2014;1(4):115–125.
- [20] Krawinkel MB, Keding GB. Bitter gourd (*Momordica charantia*): A dietary approach to hyperglycemia. *Nutr Rev* 2006;64:331–337.
- [21] Chen Q, Chan LL, Li ET. Bitter melon (*Momordica charantia*) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. *J Nutr* 2003;133:1088–1093.
- [22] Wehash FE, Abpo-Ghanema II, Saleh RM. Some physiological effects of *Momordica charantia* and *Trigonella foenum-graecum* extracts in diabetic rats as compared with cidophage®. *World Acad Sci Eng Technol* 2012;64: 1206–1214.
- [23] Nerurkar PV, Lee YK, Motosue M, Adeli K, Nerurkar VR. *Momordica charantia* (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. *Br J Nutr* 2008;100:751–759.
- [24] Chen Q, Li ET. Reduced adiposity in bitter melon (*Momordica charantia*) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines. *Br J Nutr* 2005;93: 747–754.
- [25] Huang HL, Hong YW, Wong YH, Chen YN, Chyuan JH, Huang CJ. Bitter melon (*Momordica charantia* L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats. *Br J Nutr* 2008;99:230–239.
- [26] Shih CC, Lin CH, Lin WL. Effects of *Momordica charantia* on insulin resistance and visceral obesity in mice on high-fat diet. *Diabetes Res Clin Pract* 2008;81:134–143.
- [27] Rajalakshmi A, Senthikumar B, Devi K. Antihyperglycemic and antihyperlipidemic effect of aqueous fruit extract of *Momordica charantia* against alloxan induced diabetic rats. *Int J Pharma Res Sch* 2013;2(4):54–60.
- [28] Fernandes NP, Lagishett CV, Panda VS, Suresh RN. An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized *Momordica charantia* fruit extract. *BMC Complement Altern Med* 2007;7:29.
- [29] Kolawole OT and Ayankunle AA. Seasonal variation in the anti-Diabetic and hypolipidemic effects of *Momordica charantia* fruit extract in rats. *European Journal of Medicinal Plants* 2012;2(2): 177–185.
- [30] Li X, Yi X, Shuang W, Qianchun D, Chun-Yan W, Xiang-Tao C et al. Novel bitter melon extracts highly yielded from supercritical extraction reduce the adiposity through the enhanced lipid metabolism in mice fed a high fat diet. *Journal of Nutrition & Intermediary Metabolism* 2016;6:26–32.
- [31] Wang J and Ho KR. The effects of *Momordica charantia* on obesity and lipid profiles of mice fed a high-fat diet. *Nutrition Research and Practice* 2015;9 (5):489–495.
- [32] Popovich DG, Li L and Zhang W. Bitter melon (*Momordica charantia*)

triterpenoid extract reduces preadipocyte viability, lipid accumulation and adiponectin expression in 3T3-L1 cells. Food and Chemical Toxicology 2010;48(6):1619–1626.

[33] Wakabayashi KI, Okamura M, Tsutsumi S. The peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha/heterodimer targets the histone modification enzyme PRSet7/Setd8 gene and regulates adipogenesis through a positive feedback loop. Molecular and Cellular Biology 2009;29(13):3544–3555.

[34] Nerurkar PV, Lee YK, and Nerurkar VR. *Momordica charantia* (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complementary and Alternative Medicine 2010;10:34.

[35] Puigserver P. and Spiegelman BM. Peroxisome proliferator activated receptor- α coactivator 1 α (PGC-1 α): transcriptional coactivator and metabolic regulator. Endocrine Reviews 2003;24(1):78–90.

[36] Ching RHH, Yeung LOY, Tse IMY, Sit WH, Li ETS. Supplementation of bitter melon to rats fed a high-fructose diet during gestation and lactation ameliorates fructose-induced dyslipidemia and hepatic oxidative stress in male offspring. Journal of Nutrition 2011;141(9):1664–1672.

[37] Md Ashraful Alam, Riaz Uddin, Nusrat Subhan, Md Mahbubur Rahman, Preeti Jain, and Hasan Mahmud Reza. Beneficial Role of Bitter Melon Supplementation in Obesity and Related Complications in Metabolic Syndrome. Journal of Lipids, 2015 ; 1–18.

[38] Canto C. and Auwerx J. PGC-1 α , SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Current Opinion in Lipidology 2009;20(2):98–105.

[39] Yu Y, Zhang XH, Ebersole B, Ribnicky D, Wang ZQ. Bitter melon extract attenuating hepatic steatosis may be mediated by FGF21 and AMPK/Sirt1 signaling in mice. Scientific Reports 2013;3:3142.

[40] Peet DJ, Turley SD, Ma W. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR- α Cell 1998;93(5):693–704.

[41] Matsui S, Yamane T, Takita T, Oishi Y, Kobayashi-Hattori K. The hypocholesterolemic activity of *Momordica charantia* fruit is mediated by the altered cholesterol- and bile acid-regulating gene expression in rat liver. Nutrition Research 2013;33(7):580–585.

[42] Chikkavadaragudi RS, Vishwanath P, Prashant A, Rangaswamy C, Maduvanahalli NS, Hattur B. Fifty percent ethanolic extract of *Momordica charantia* inhibits adipogenesis and promotes adipolysis in 3T3-L1 pre-adipocyte cells. Rep Biochem Mol Biol 2017;6(1):23–32.

[43] Hulin A. Intoxication aigue par *Momordica charantia* (sorrossi). A propos de deux cas (acute intoxication due to *Momordica charantia* (sorrossi). Study of two cases). Sem. Hop 1988;64:2847–2848.

[44] Dans AM, Villarruz MV, Jimeno CA, Javelosa MA, Chua J, Bautista R. The effect of *Momordica charantia* capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J Clin Epidemiol 2007;60:554–559.

[45] Dutta PK, Chakravarty AK, Chowdhury US, Pakrashi SC. Vicine, a Favism-inducing toxin from *Momordica charantia* Linn. seeds. Indian J Chem 1981;20:669–671.

[46] Deshaware S, Gupta S, Singhal RS, Joshi M, Variyar PS. Debittering of

bitter gourd juice using β -cyclodextrin:
Mechanism and effect on antidiabetic
potential. Food Chem 2018;262:78–85.

[47] Tan SP, Kha TC, Parks SE,
Stathopoulos CE, Roach PD. Effects of
the spray-drying temperatures on the
physiochemical properties of an
encapsulated bitter melon aqueous
extract powder. Powder Technol 2015;
281:65–75.